Group 1 - The core point of the article is that JPMorgan has increased its stake in Guangzhou Pharmaceutical Holdings (00874) by purchasing 360,600 shares at a price of HKD 18.8482 per share, totaling approximately HKD 6.7967 million [1] - After the purchase, JPMorgan's total shareholding in Guangzhou Pharmaceutical Holdings is approximately 20.0603 million shares, representing a holding percentage of 9.12% [1]

Group 1 - The core point of the article is that JPMorgan has increased its stake in Guangzhou Pharmaceutical Holdings (00874) by purchasing 360,600 shares at a price of HKD 18.8482 per share, totaling approximately HKD 6.7967 million [1] - After the purchase, JPMorgan's total shareholding in Guangzhou Pharmaceutical is approximately 20.0603 million shares, representing a holding percentage of 9.12% [1]

2月2日，A股上市药企白云山（证券代码：600332）发布公告显示，公司参与合作设立的广州广药广开创业投资基金合伙企业（有限合伙）（"广药广开基 金"）已于今年1月完成工商登记、取得营业执照，并在中国证券投资基金业协会完成备案手续。公告同时披露，广药广开基金首期实缴出资合计1.2亿元。 广药广开基金出资方及出资比例为广开基金占50%、广药二期基金占48.75%、广药资本占1.25%。其中，出资占比最多的广开基金为黄埔投资控股（广州） 有限公司和广州金控基金管理有限公司的合资公司。 白云山公告显示，近日该公司接到广药资本的通知，广药广开基金已于2026年1月30日在中国证券投资基金业协会完成备案手续，并取得了《私募投资基金 备案证明》。 根据备案信息，该基金名称为广州广药广开创业投资基金合伙企业（有限合伙），管理人名称为广州广药资本私募基金管理有限公司，托管人名称为招商银 行股份有限公司。 白云山在此次公告中表示，本次投资符合广药二期基金的投资方向，有利于扩大广药二期基金投资规模、分散投资风险及加快投资步伐、提高投资效率，将 加强白云山在创新药、现代中药、高端医疗器械等生物医药前沿领域的布局，通过"投早、投小、 ...

Core Viewpoint - The company Baiyunshan has established a new venture capital fund, Guangzhou Guangyao Guangkai Venture Capital Fund, with a total initial capital contribution of 120 million yuan, aimed at enhancing its investment in innovative pharmaceuticals and medical devices [2][5]. Group 1: Fund Establishment and Registration - Baiyunshan announced the completion of the business registration and acquisition of a business license for the Guangzhou Guangyao Guangkai Venture Capital Fund in January 2026 [2][5]. - The fund has been registered with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [5]. Group 2: Investment Details - The total initial capital contribution for the fund is 120 million yuan, with Baiyunshan's subsidiary contributing 9.75 million yuan [3][6]. - The fund's capital structure includes 50% from Guangkai Fund, 48.75% from Guangyao Phase II Fund, and 1.25% from Guangyao Capital [5]. Group 3: Strategic Implications - The investment aligns with the strategic direction of Guangyao Phase II Fund, aiming to expand investment scale, diversify risks, and accelerate investment pace [5]. - Baiyunshan intends to strengthen its position in cutting-edge biomedicine fields through early-stage investments in promising companies, facilitating technological upgrades and extending its value chain [5]. Group 4: Overall Investment Situation - Baiyunshan's total investment in various private equity funds has reached 587 million yuan, with the largest investment being 390 million yuan in the Guangzhou Guangyao Chuantou Venture Capital Fund [6].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 2. 股份 ...

证券代码：600332 证券简称：白云山 公告编号：2026－003 企业名称：广州白云山明兴制药有限公司 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广州白云山明兴制药有限公司（以下简称"明兴药业"）收 到广东省药品监督管理局核准签发的《药品生产许可证》，同意明 兴药业变更生产车间名称及核减生产范围、生产车间、生产线。现将 相关情况公告如下： 一、《药品生产许可证》基本情况 许可证编号：粤 20160012 分类码：AhzxBzDhz 注册地址：广州市海珠区工业大道北 48 号 发证机关：广东省药品监督管理局 有效期至：2030 年 10 月 8 日 生产地址和生产范围： 1 钠、氯膦酸二钠、硝酸甘油溶液、盐酸乙胺丁醇、烟酸），中药前处 理及提取车间（口服制剂）；4、广州市白云区健旭三路 99 号，硬胶 囊剂，颗粒剂，小容量注射剂（含非最终灭菌），冻干粉针剂，原料 药（人工牛黄），冻干 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 第 1 頁 共 10 頁 v 1.2.0 FF301 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RM ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 中國廣州，2026年2月3日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2026－003 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥品生產許可證變更的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公 ...

Core Viewpoint - The Guangzhou Pharmaceutical Group is entering a new phase of brand development with the establishment of the Brand Strategy Committee, focusing on a comprehensive brand strategy for the next five years [1]. Group 1: Brand Strategy and Management - The brand strategy framework is centered around "1+6," where "1" represents a unified brand strategy plan and "6" signifies six key strategic initiatives [1]. - The establishment of the Brand Strategy Committee marks a significant step in the company's brand construction efforts [1]. Group 2: Business Performance and Growth - The company aims to double its business performance, with key strategies including regional expansion and internationalization of technology innovation [4]. - The acquisition of Caishantang is highlighted as a successful case of regional expansion, achieving a fourfold revenue increase after expanding its market presence beyond Fujian Province [4]. Group 3: Scientific Research and Internationalization - The company emphasizes the importance of scientific research to validate the effectiveness of traditional Chinese medicine, aiming for international collaboration with research institutions in North America and Europe [5][6]. - Recent achievements include the publication of a product in a top international journal and the recognition of another product in Russia, showcasing the potential for traditional medicine to be integrated into global healthcare solutions [6]. Group 4: Strategic Partnerships and Capital Operations - Under the leadership of Li Xiaojun, the company has accelerated its capital operations and formed strategic partnerships, including a collaboration with Huawei to enhance its international strategy [7]. - The company has made significant investments in innovative drugs and high-end medical devices, with plans for substantial R&D and investment in the coming years [7]. Group 5: Policy Recommendations and Industry Development - Li Xiaojun has proposed measures to support the biopharmaceutical industry, including establishing a systematic error-correction mechanism and creating a global talent network [8]. - Recommendations also include developing a collaborative response mechanism for international trademark disputes to support companies venturing abroad [8].

本次奇星药业委托白云山制药总厂生产虚汗停颗粒(无糖型)在原委托生产地址基础上，新增受托生产地 址，有利于其增加产能，提高生产效率，满足市场需求。本次获得《药品生产许可证》，对本公司当期 业绩无重大影响。 智通财经APP讯，白云山(00874)发布公告，近日，公司子公司广州白云山奇星药业有限公司(简称"奇星 药业")收到广东省药品监督管理局核准签发的《药品生产许可证》，同意奇星药业委托广州白云山医药 集团股份有限公司白云山制药总(简称"白云山制药总厂")厂生产虚汗停颗粒(无糖型)在原委托生产地址 基础上，新增受托生产地址。 ...